Ionetix Corp / DE / 8-K filed 2026

Item 7.01 – Regulation FD Disclosure

On May 26, 2026, Ionetix Corporation (the “Company”) issued
a press release announcing that the United States Food and Drug Administration has approved the Company’s Abbreviated New Drug Application
(ANDA) for Gallium Ga-68 gozetotide (PSMA-11).

A copy of the press release is being furnished with this Current Report
on Form 8-K as Exhibit 99.1 and is hereby incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1, is being
furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities under that Section, nor shall it be deemed to be incorporated by
reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference.

Safe Harbor for Forward-Looking and Cautionary Statements

This Current Report on Form 8-K contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and
are made pursuant to the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking
statements may be identified by terminology such as “may,” “should,” “expect,” “intend,”
“plan,” “anticipate,” “believe,” “estimate,” “predict,” “will,”
“could,” “project,” “target,” “potential,” “continue,” and similar expressions.
Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those described in the
forward-looking statements, including the risks described in the Company’s filings with the Securities and Exchange Commission.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company undertakes
no obligation to update any forward-looking statements except as required by law.
Ionetix Corp / De / - 8-K

Item 7.01 - Regulation FD Disclosure

Item 9.01 - Financial Statements and Exhibits
